VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Akums Drugs will undertake this development and commercialization in India
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Subscribe To Our Newsletter & Stay Updated
